Airtame Launches Airtame Cloud, Signaling New Focus on Combined Hardware and Software Offering
15.1.2020 16:00:00 EET | Business Wire | Press release
Airtame, the leading wireless screen sharing and collaboration platform, today announced the official launch of Airtame Cloud, a new software-as-a-service product designed to make screens smarter. The open platform offers device management and access to a range of digital signage solutions, helping users create smarter offices, workplaces and schools with their screens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200115005060/en/
Airtame Cloud (Graphic: Business Wire)
Airtame Cloud -- which has been available in beta for over a year, and is already used by 6,500 organizations globally -- is a unified platform that enables users to manage and update their screens remotely. It was built on an open ecosystem that seamlessly integrates with a range of applications that can be used to create tailored digital signage, such as Google Slides, Microsoft OneDrive, Trello, Dropbox, and YouTube, with more integrations to come.
Cloud will allow users to:
- Manage screens remotely, freeing up IT administrators to change settings and conduct bulk updates with cloud access to Airtame-enabled screens
- Boost productivity and engagement, with personalized digital signage in meeting rooms, classrooms and common areas
- Save on power, by scheduling screens to turn on and off according to office or school hours
- Avoid blank screens, by scheduling imagery and videos to play on loop
The launch of Cloud marks the evolution of Airtame as it continues to grow from a hardware to solution-centric business, with a strong focus on facilitating smart offices and schools around the world.
“With Airtame Cloud, we’re providing a solution that empowers our customers to boost engagement and productivity for employees, students and visitors, whether that be in the office, meeting room or classroom,” said Airtame Co-Founder and Co-CEO Jonas Gyalokay.
“Part of our vision at Airtame is to help enterprises and schools create smarter offices and classrooms. While this starts with screens, we imagine one day it could extend to all aspects of the workplace or classroom, with the potential to automate lighting, sound, room temperature and more.
“With the evolution of IoT, the possibilities to connect devices and screens are endless. As a starting point, Airtame Cloud will help schools and enterprises reduce their energy consumption by automating screens to turn off when they’re not being used. We’re looking forward to embracing technology to build additional hardware and software features of this kind in the future.”
Airtame Cloud will launch with two plans: Airtame Cloud Lite, a free version of the product that offers the essential features needed to manage and update Airtame devices, and Airtame Cloud Plus, a premium version that enables digital signage and additional features needed to create a smart office or classroom.
The launch follows a series of important milestones for Airtame, including the recent announcement of its industry-first partnership with Airserver. The company has enjoyed 100% YoY growth since its market launch in 2014.
ENDS
Access the full press kit containing imagery and video materials here.
ABOUT AIRTAME:
Airtame offers a wireless screen sharing and collaboration platform that allows users to instantly display content from any personal device to any shared screen. The platform is used to promote interactivity and collaboration in meetings, presentations and classroom settings, as well as for digital signage in retail stores, corporate environments, conference facilities, hotels, and other venues. Airtame was launched in 2014 and has grown into a company with 100+ people, and with offices in New York, Los Angeles, Copenhagen, and Budapest.
To learn more, visit www.airtame.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005060/en/
Contact information
Martin Stockfleth Larsen
Airtame
+45 31 661 663
martin.larsen@airtame.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom